#1 Clinical Trials Search in Europe

Immunoglobulin A

This article summarizes several clinical trials investigating the use of vibostolimab (MK-7684A), a novel immunotherapy drug, in combination with pembrolizumab for treating various types of cancer. The trials aim to evaluate the safety and efficacy of this combination therapy compared to standard treatments in patients with lung cancer, melanoma, colorectal cancer, and bladder cancer. These studies represent important research efforts to improve outcomes for patients with advanced cancers that have not responded well to existing therapies.

Table of Contents

What is MK-7684A?

MK-7684A is an investigational drug combination being developed for cancer treatment. It consists of two medications:[1]

  • Vibostolimab: A new immunotherapy drug that targets a protein called TIGIT
  • Pembrolizumab: An established immunotherapy drug that targets PD-1

This combination is given as an intravenous infusion, typically every few weeks. MK-7684A is being studied as a potential treatment for various types of cancer.

How does MK-7684A work?

MK-7684A works by helping activate the body’s immune system to fight cancer:[2]

  • Vibostolimab blocks a protein called TIGIT on immune cells. TIGIT normally helps keep the immune system in check, but blocking it can boost immune responses against cancer.
  • Pembrolizumab blocks PD-1, another protein that restrains immune cells. By blocking PD-1, it helps activate cancer-fighting immune cells.

By targeting two different immune checkpoints (TIGIT and PD-1), the combination aims to produce a stronger anti-cancer immune response than either drug alone.

What conditions is MK-7684A being studied for?

MK-7684A is currently being investigated for several types of cancer, including:[3][4][5][6][7]

  • Non-small cell lung cancer (NSCLC): Both early stage and advanced disease
  • Small cell lung cancer (SCLC): Extensive-stage disease
  • Melanoma: High-risk, resected (surgically removed) melanoma
  • Colorectal cancer: Advanced colorectal cancer with specific genetic features (MSI-H/dMMR)
  • Bladder cancer: Non-muscle invasive bladder cancer that has not responded to standard treatments

Clinical Trials of MK-7684A

MK-7684A is being studied in several ongoing clinical trials:[3][4][5][6][7]

  • NSCLC: A phase 2 study is comparing MK-7684A to standard chemotherapy in patients with advanced NSCLC that has progressed after initial treatment.
  • Melanoma: A phase 3 trial is evaluating MK-7684A as an adjuvant (additional) treatment after surgery for high-risk melanoma.
  • Colorectal cancer: A phase 2 study is comparing MK-7684A to other treatments in patients with advanced MSI-H/dMMR colorectal cancer.
  • Bladder cancer: A phase 2 trial is studying MK-7684A in patients with high-risk non-muscle invasive bladder cancer that hasn’t responded to standard therapy.
  • SCLC: A phase 3 study is comparing MK-7684A plus chemotherapy to standard treatment in patients with extensive-stage small cell lung cancer.

Potential Benefits of MK-7684A

While research is still ongoing, MK-7684A may offer several potential benefits:[3][4][5][6][7]

  • Improved efficacy: By targeting two immune checkpoints, MK-7684A may produce stronger anti-cancer effects than single-agent immunotherapies.
  • Broader applicability: It’s being studied in multiple cancer types, potentially offering a new option for patients with different forms of cancer.
  • Treatment for resistant cancers: MK-7684A may help patients whose cancers haven’t responded to other treatments.
  • Quality of life improvements: Some trials are specifically measuring whether MK-7684A can improve cancer-related symptoms and overall quality of life.

Possible Side Effects

As with all medications, MK-7684A may cause side effects. Common side effects of immunotherapy drugs like those in MK-7684A can include:[3][4][5][6][7]

  • Fatigue
  • Skin rash or itching
  • Diarrhea
  • Nausea
  • Decreased appetite
  • Joint pain

More serious side effects are possible, including inflammation in various organs. Patients in clinical trials are closely monitored for any adverse reactions.

Conclusion

MK-7684A represents a promising new approach in cancer immunotherapy. By combining two drugs that target different immune checkpoints, it aims to enhance the body’s ability to fight cancer. While still in clinical trials, MK-7684A is being studied for multiple types of cancer and may offer hope for patients who have limited treatment options. As research continues, we’ll learn more about its effectiveness and safety profile.

Cancer Type Trial Phase Key Comparisons Primary Endpoints
Non-small cell lung cancer (NSCLC) Phase 2 MK-7684A + docetaxel vs. docetaxel alone Progression-free survival
Melanoma Phase 3 MK-7684A vs. pembrolizumab Recurrence-free survival
Colorectal cancer Phase 2 MK-7684A vs. pembrolizumab and other combinations Objective response rate
Bladder cancer Phase 2 MK-7684A vs. pembrolizumab Complete response rate
Small cell lung cancer (SCLC) Phase 3 MK-7684A + chemotherapy vs. atezolizumab + chemotherapy Overall survival

FAQ

  • What is vibostolimab (MK-7684A)? Vibostolimab (MK-7684A) is an investigational immunotherapy drug that is being studied in combination with pembrolizumab. It is an antibody that targets a protein called TIGIT, which is involved in regulating the immune system's response to cancer cells.
  • What types of cancer are being studied with vibostolimab? The clinical trials are investigating vibostolimab for several types of cancer, including non-small cell lung cancer, small cell lung cancer, melanoma, colorectal cancer, and bladder cancer.
  • How is vibostolimab given to patients? Vibostolimab is administered as an intravenous infusion, typically in combination with pembrolizumab and sometimes with other cancer treatments like chemotherapy.
  • What are the main goals of these clinical trials? The main goals are to evaluate the safety and effectiveness of vibostolimab in combination with other treatments. The trials are measuring outcomes like overall survival, progression-free survival, and tumor response rates compared to standard therapies.
  • Who is eligible to participate in these clinical trials? Eligibility varies by trial, but generally includes adult patients with specific types and stages of cancer who meet certain health criteria. Some trials focus on patients whose cancer has not responded to previous treatments.

Ongoing Clinical Trials on Immunoglobulin A

  • Study on the Effectiveness and Safety of IgM-Enriched Immunoglobulin Therapy for Patients with Septic Shock

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effects of Immunoglobulin A, G, and M in Patients with Peritonitis and Sepsis After Infection Control

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany

  • Study on Pentaglobin for Treating Fever in Acute Leukemia or Stem Cell Transplant Patients with Resistant Bacteria

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Vibostolimab: An investigational immunotherapy drug that targets the TIGIT protein to enhance the immune system's ability to fight cancer cells.
  • Pembrolizumab: An immunotherapy drug that helps the immune system detect and fight cancer cells by blocking a protein called PD-1.
  • MK-7684A: A combination therapy consisting of vibostolimab and pembrolizumab.
  • TIGIT: T cell immunoreceptor with Ig and ITIM domains, a protein involved in regulating immune responses.
  • Non-small cell lung cancer (NSCLC): A type of lung cancer that includes several subtypes, such as adenocarcinoma and squamous cell carcinoma.
  • Small cell lung cancer (SCLC): A fast-growing type of lung cancer that often spreads quickly.
  • Melanoma: A type of skin cancer that develops in melanocytes, the cells that produce pigment.
  • Colorectal cancer: Cancer that starts in the colon or rectum.
  • Bladder cancer: Cancer that begins in the cells lining the bladder.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-mk-7684a-and-docetaxel-for-treating-metastatic-non-small-cell-lung-cancer-in-patients-after-platinum-chemotherapy-and-immunotherapy/
  2. http://clinicaltrials.eu/trial/study-comparing-mk-7684a-vibostolimab-and-pembrolizumab-with-pembrolizumab-for-adults-and-children-with-high-risk-melanoma/
  3. http://clinicaltrials.eu/trial/study-comparing-mk-7684a-vibostolimab-and-pembrolizumab-with-pembrolizumab-for-adults-and-children-with-high-risk-stage-ii-iv-melanoma/
  4. http://clinicaltrials.eu/trial/study-comparing-mk-1308a-and-pembrolizumab-for-patients-with-advanced-colorectal-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency/
  5. http://clinicaltrials.eu/trial/study-of-pembrolizumab-vibostolimab-and-favezelimab-for-patients-with-high-risk-non-muscle-invasive-bladder-cancer-unresponsive-to-bcg-therapy/
  6. http://clinicaltrials.eu/trial/study-of-mk-7684a-with-chemoradiotherapy-compared-to-chemoradiotherapy-with-durvalumab-for-patients-with-stage-iii-non-small-cell-lung-cancer/
  7. http://clinicaltrials.eu/trial/study-of-mk-7684a-etoposide-and-platinum-drugs-for-patients-with-extensive-stage-small-cell-lung-cancer/